Market closedNon-fractional
Nektar Therapeutics/NKTR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Ticker
NKTR
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
San Francisco, United States
Employees
137
Website
www.nektar.com
NKTR Metrics
BasicAdvanced
$237M
Market cap
-
P/E ratio
-$0.92
EPS
0.71
Beta
-
Dividend rate
Price and volume
Market cap
$237M
Beta
0.71
Financial strength
Current ratio
6.103
Quick ratio
5.588
Long term debt to equity
167.765
Total debt to equity
183.051
Interest coverage (TTM)
-5.47%
Management effectiveness
Return on assets (TTM)
-17.31%
Return on equity (TTM)
-95.68%
Valuation
Price to revenue (TTM)
2.739
Price to book
1.87
Price to tangible book (TTM)
1.87
Price to free cash flow (TTM)
-1.306
Growth
Revenue change (TTM)
1.51%
Earnings per share change (TTM)
-58.45%
3-year revenue growth
-10.55%
3-year earnings per share growth
-27.27%
What the Analysts think about NKTR
Analyst Ratings
Majority rating from 4 analysts.
NKTR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$22M
-9.24%
Net income
-$37M
-12.38%
Profit margin
-170.37%
-3.46%
NKTR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.27
-$0.24
-$0.22
-$0.19
-
Expected
-$0.28
-$0.20
-$0.21
-$0.19
-$0.20
Surprise
-4.89%
20.34%
3.58%
0.00%
-
NKTR News
AllArticlesVideos
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
PRNewsWire·3 weeks ago
Nektar Management to Present at Upcoming Investor Conferences
PRNewsWire·1 month ago
Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $237M as of July 06, 2024.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of July 06, 2024.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Nektar Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.